GELL_LATAM

We are the most important LATAM group in the study of Lymphoproliferatives. Includes more than 12 countries.

[GELL_LATAM @GELL01433166]

Jain P etal. Am J Hematol 2021;96(1):165-166. Triple-hit MYC-BCL6-CCND1 with deleted TP53 is a very rare and high risk category of #mcl. #lymsm

[GELL_LATAM @GELL01433166]

Pola R etal. Acta Biomater 2021;119:349-359. Cytarabine nanotherapeutics in #mcl treatment. The results provide sound preclinical rationale for the use of nanoparticle-based araC co-polymers in induction, salvage or palliative therapy of MCL patients. #lymsm

[GELL_LATAM @GELL01433166]

Neerav M etal. Crit Rev Oncol Hematol 2021;158:103212. Systematic review of first-line of treatment #mcl. In elderly patients ineligible for transplant, OS ranged from 40m to 69.6m. In young transplant-eligible patients, OS ranged from 53m to 152.4m. #lymsm @hematologo

[GELL_LATAM @GELL01433166]

Le Gouill S et al. Blood 2021;137(7):877. Phase 1/2 Ibrutinib,venetoclax,obinutuzumab. #mcl untreated/relapse. The combination is well tolerated and provides high RR, including molecular level, in relapsed and untreated MCL patients.1-year PFS 93.3% (95% CI, 81.5%-100%) #lymsm

[GELL_LATAM @GELL01433166]

Marco Ladetto et al. Lancet Haematol2021;8(1):e34. Len in maintenance for #MCL #lymsm. Conclusion: Despite non-negligibile toxicity, len after ASCT improved PFS in patients with MCL, highlighting the role of maintenance in MCL.

[GELL_LATAM @GELL01433166]

Sondas Alsharidah et al. COVID-19 convalescent plasma treatment of moderate (HR=1.9) and severe (HR=2.5) cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis 2021 Feb;103:439-446. Non-random study, all patients with supplemental 02. @hematologo

[Juan Rangel MD @rajuan_27]

Hoy me dijo el “viene viene” que cuando le iba a dar su aguinaldo...😒

Ni a mi me dan aguinaldo ya que estoy contratado por honorarios

[GELL_LATAM @GELL01433166]

propofol? The use of propofol is common in intubated patients and the green urine occurred commonly 48hrs after start its use. @NEJM

[NEJM @NEJM]

A 62-year-old man with chronic obstructive pulmonary disease came to the ED with 2 days of dyspnea. He was admitted to the ICU while in hypercapnic respiratory failure and placed on intubation and ventilation. Five days later, his urine became green. Which medication caused this?

[Dr. Luis Villela @hematologo]

Today, #ASH20 meeting start!! ⁦⁩ #ASHkudos to ⁦@ASH_hematology⁩ . enjoy this new form to share with my colleagues.

[GELL_LATAM @GELL01433166]

A total of 17 (6.5%) patients had clonal somatic mutations. were also associated with inferior OS in the univariate (HR=2.06, p=0.053),attenuated after multivariate adjustment (HR=1.59, p=0.22).
I think, low incidence for being use in clinic @JohnPLeonardMD

[John P. Leonard, MD @JohnPLeonardMD]

Now for #LeonardList #ASH20 top #lymphoma abstract daily countdown - Number 9 - 534 - Boddicker - Clonal Somatic Mutations in pts w/Diffuse Large B Cell Lymphoma and correlation w/prognosis - collaboration w/ #Lymphoma Epidemiology of Outcomes study https://t.co/AUbjoEaFg6

[GELL_LATAM @GELL01433166]

However, if you observe type of population, more than 60% were ARDS mild (using low-flow O2). In our study TERAPLASCOV2 (registered in clinical trials) phase1/2, we observed that paO2/FiO2 is very important for getting an outcome. You can see at #ASH20.
https://t.co/rH9Pq85XmH

[Eric Topol @EricTopol]

Randomized, placebo-controlled trial of convalescent plasma(CP) for severe #COVID19: "no significant differences...in clinical status or overall mortality" @NEJM
"We believe the use of CP as a standard of care....should be reevaluated." https://t.co/RcSH2p1Oh2

[GELL_LATAM @GELL01433166]

Phase 1b. Ibrutinib+rituximab+lenalidomide in Primary CNS lymphoma. Presented by @GrommesChristian. Patients with CNS lymphoma tolerate the combination well. No dose limiting toxicities were observed. Continued enrollment is ongoing #ASH20 #ASH2020 #lymsm

[GELL_LATAM @GELL01433166]

Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma. Presented by @TakataKatsuyoshi. Highlight populations may benefit from LAG3 checkpoint inhibition. #ASH20 #ASH2020

[GELL_LATAM @GELL01433166]

Sin lugar a duda conocer la opinión de los pacientes ayudará a individualizar el tratamiento.

[Raul Cordoba, MD, PhD @DrRaulCordoba]

“Conocer la opinión del paciente permite individualizar la atención en tiempo real”. Gracias @larazon_es por haceros eco de “E-Res Salud”, programa de evaluación de resultados en salud #VBHC que @UICOquironsalud ha comenzado en los hospitales públicos @quironsalud #PROMs #PREMs

[Andres Gomez @GomezDLeonMD]

Day 0. For her, a moment of contemplation and prayer. Send good vibes. #Bmtsm

[Dr. Luis Villela @hematologo]

|￣￣￣￣￣￣￣￣￣￣￣|
Esta cuenta
pide
que uses cubrebocas 😷
|＿＿＿＿＿＿＿＿＿＿＿|
(\__/) ||
(•���•) ||
/ づ

[GELL_LATAM @GELL01433166]

Subcutaneous panniculitis-type T-cell lymphoma. Bad prognostic. @vittodr

[NEJM @NEJM]

A 29 yo male presented with 6 months of progressive painless lesions, with no systemic symptoms. Biopsy showed diffuse dermal infiltrate, blast-like cells extending to the hypodermis. Immunohistochemical analysis tested positive for CD4, CD56 & CD123. What is the diagnosis?

[NEJM @NEJM]

A recent study of a mouse model of placental infection showed that decidual natural killer cells tackle Listeria monocytogenes through a stealth attack involving actin nanotubes.

[JAMA @JAMA_current]

Editing the genome of a single-celled embryo is expected to prevent serious disorders beyond the reach of contemporary medicine. The promise of human genome editing must be deferred until it passes technical, regulatory & public muster https://t.co/4Elay7zxKS @eadashi @CohenProf

[Eric Topol @EricTopol]

Without head-to-head trials, it's hard to make inferences about efficacy w/certainty, but the drop-off is noteworthy for this vaccine (62%) compared w/ @BioNTech_Group and @moderna_tx (~95%).
A claim of "up to 90%" based on a subgroup that is peculiar (??"priming") doesn't help.